News


All series


All News

A pre-planned subgroup analysis of data from the MONALEESA-2 trial demonstrated similar clinical benefit and safety profiles in elderly patients compared to younger patients with HR+/HER2-advanced breast cancer, supporting a paradigm shift in the future medical management of these patients from the current standard of letrozole to combined treatment of letrozole plus ribociclib.

Lead study author Jennifer A. Woyach, MD, discusses a phase II trial of MOR208, which includes cohorts of patients with relapsed/refractory CLL, treatment-naïve disease, Richter’s transformation, and those with CLL who have been treated with ibrutinib.

According to results from a randomized clinical trial,<sup>&nbsp;</sup>adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with <em>BRAF</em>-mutant metastatic colorectal cancer.

Supporting the concept of post-progression survival and the influence of different patterns of progression, a new analysis showed patients with advanced HCC had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression.